AMG 837

AMG 837 Suppliers list
Company Name: Shanghai EFE Biological Technology Co., Ltd.  
Tel: 021-65675885 18964387627
Email: info@efebio.com
Company Name: Shanghai Hongye Biotechnology Co. Ltd  
Tel: 400-9205774 400-920-5774
Email: sales@glpbio.cn
Company Name: BOC Sciences  
Tel: 16314854226; +8616314854226
Email: inquiry@bocsci.com
Company Name: BOC Sciences  
Tel: 16314854226
Email: info@bocsci.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
AMG 837 Basic information
Product Name:AMG 837
Synonyms:AMG 837 calcium salt;AMG 837 hemicalcium salt;(βS)-β-1-Propyn-1-yl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]benzenepropanoic acid hemicalcium salt;AMG 837 hemicalcium;(βS)-β-1-Propyn-1-yl-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-3-yl]methoxy]benzenepropanoicacidhemicalciumsalt
CAS:1291087-14-3
MF:C26H23CaF3O3
MW:480.54
EINECS:
Product Categories:
Mol File:1291087-14-3.mol
AMG 837 Structure
AMG 837 Chemical Properties
storage temp. Store at -20°C
solubility Soluble in DMSO
Safety Information
MSDS Information
AMG 837 Usage And Synthesis
UsesAMG 837 Hemicalcium Salt is used in the synthetic preparation of a novel GPR40 receptor agonist, AMG 837 (A614410). GPR40 is a polyunsaturated fatty acid receptor that is involved with many systemic effects, which are beneficial for metabolic and inflammatory diseases. GPR40 has also been implicated as a target for treating obesity.
in vivo

AMG 837 (0.03-0.3 mg/kg; a single p.o.) improves glucose tolerance and enhances insulin secretion in Sprague-Dawley rats[1].
AMG 837 (0.03-0.3 mg/kg; p.o. once daily for 21 days) reduces glucose levels and increases insulin levels following glucose challenge in vivo[1].
AMG 837 (0.5 mg/kg; p.o.) displays excellent oral bioavailability (F=84%) and a total plasma Cmax of 1.4 μM[1].

Animal Model:8-week old Zucker Fatty Rats[1]
Dosage:0.03, 0.1, 0.3 mg/kg
Administration:Oral gavage once daily for 21 days
Result:Decreased glucose AUC values during the glucose tolerance test (GTT) to 7%, 15%, and 25% at 0.03, 0.1 and 0.3 mg/kg, respectively.
Increased insulin levels in the mid- and high-dose groups.
Not affected body weights during the 21-day treatment.
Animal Model:8-week old Sprague-Dawley rats[1]
Dosage:0.03, 0.1, 0.3 mg/kg
Administration:A single p.o. administration
Result:Reduced the post-prandial glucose with the half-maximal dose of 0.05 mg/kg.
storageStore at +4°C
AMG 837 Preparation Products And Raw materials
Tag:AMG 837(1291087-14-3) Related Product Information
GW-1100 SCO-267 4-{3-nitrophenyl}-2-methyl-N-(2-methylphenyl)-5-oxo-1,4,5,6,7,8-hexahydro-3-quinolinecarboxamide 4-Methoxy-N-(2,4,6-triMethylphenyl)benzenesulfonaMide, 97% TUG 891 CATPB